Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Lancet Oncol. 2013 Oct;14(11):e447-e456. doi: 10.1016/S1470-2045(13)70173-6.
Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have led to these delays and describe how they are progressively being overcome. Recent and striking successes and correspondingly increased commercial involvement suggest that gene transfer could finally become a powerful method for development of safe and effective cancer therapeutic drugs.
基因治疗被视为治疗癌症的一种很有前途的方法，但在实施方面却收效甚微，这种缺陷随着越来越多的此类方法成功纠正单基因疾病的报道而变得更加明显。我们回顾了导致这些延迟的商业和科学障碍，并描述了它们是如何逐步被克服的。最近引人注目的成功和相应增加的商业参与表明，基因转移最终可能成为开发安全有效的癌症治疗药物的一种强大方法。
